+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4661514
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 175 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Alloksys
  • AM Pharma
  • Angion Biomedica
  • Astellas Pharma
  • Atox Bio
  • Exponential Biotherapies
  • MORE
The ‘Acute Kidney Injury (AKI)- Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AKI in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of AKI from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017–2028.

Acute Kidney Injury (AKI) - Disease Understanding and Treatment Algorithm

AKI is characterized by a rapid fall in glomerular filtration rate, clinically manifest as an abrupt and sustained rise in urea and creatinine. Life threatening consequences include volume overload, hyperkalaemia, and metabolic acidosis. As per the American Kidney Foundation organization, AKI was formerly called Acute Renal Failure. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes. Acute Kidney Injury is classified into three different phases including prerenal, postrenal and intrinsic renal. Pre-renal ARI is characterized by inadequate blood circulation to the kidneys, which leaves them to clean the body properly. Post-renal is characterized by acute obstruction to urinary flow which increases intratubular pressure and decreases GFR. Intrinsic AKI is the third type, which shows direct damage to kidneys by inflammation, toxins, drugs, and infections. The risk factors associated with AKI include age, exposure to nephrotoxins, family history, race and ethnicity, gender and others.

The Acute Kidney Injury market report gives the thorough understanding of the AKI by including details such as disease introduction, signs and symptoms, types of AKI, risk factors, causes, pathophysiology, stages of classification, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for AKI in the US, Europe, and Japan.

Acute Kidney Injury (AKI) Epidemiology

AKI, which is also known as Acute Renal Failure is characterized by azotemia that progresses over several hours or days, with or without oliguria. It is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Acute Kidney Injury in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028 for the following aspects:
  • Incident Cases of Acute Renal Failure in the United States
  • Discharge Diagnosed Cases of Acute Renal Failure in the United States
  • Stage-Wise Discharged Diagnosed Cases of Acute Renal Failure in the United States
  • Risk Factor Associated Acute Renal Failure Cases in the United States
  • Renal Transplantation Associated Delayed Graft Function Cases in the United States
Risk factors associated with AKI has been observed from the study conducted by Orfeas Liangos et al. entitled, “Epidemiology and Outcomes of Acute Renal Failure in Hospitalized Patients: A National Survey”. In the study, various risk factors are associated with ARF includes, Coronary artery disease, Congestive heart failure, Chronic kidney disease, Chronic lung disease, Cancer, Diabetes, Hypertension and HIV infection. The study also summarized that discharge diagnosis of ARF was also more commonly assigned to individuals with a coexisting diagnosis of congestive heart failure, chronic lung disease, chronic kidney disease, cancer, and HIV infection but less commonly to individuals with a coexisting diagnosis of coronary artery disease, diabetes, and hypertension.

Stage specific incident cases of acute kidney injury has been estimated on the basis of study conducted by Ostermann et al. entitled, “Challenges of defining acute kidney injury”. This study compares the performance of the different ARF definitions. In this study, patients were segregated on the basis of stages in RIFLE and AKIN classification. The RIFLE criteria and the AKIN classification led to similar total incidences of ARF but different incidences and outcomes of the individual ARF stages. Although, the AKIN classification demonstrated a stepwise increase in risk of mortality.

Acute Kidney Injury (AKI) Drug Chapters

This segment of the Acute Kidney Injury report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment Acute Kidney Injury, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Acute Kidney Injury & awareness of the disease. The overall dynamics of Acute Kidney Injury market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Exponential Biotherapies, Alloksys, Atox Bio, Pharming Technologies, Angion Biomedica, Quark Pharmaceutical, Astellas Pharma, AM Pharma, Orion Pharma and MediBeacon will significantly increase the market during the forecast period (2019–2028).

Acute Kidney Injury (AKI) Market Outlook

AKI is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. Robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of Acute Kidney Injury market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of market which presently comprises of Biologics and molecules with new mechanisms of action. Currently, there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of Acute Kidney Injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs, which include various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Acute Kidney Injury in 7MM is expected to change from 2019–2028.

Acute Kidney Injury (AKI) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Acute Kidney Injury (AKI) such as ANG-3777 (BB3; Angion Biomedica), QPI1002 (Quark Pharmaceutical), ASP1128 (Astellas Pharma), MB-102 (MediBeacon), Ruconest (Conestat alfa; Pharming Technologies), recAP (AM Pharma), bRESCAP (Alloksys), Reltecimod (Atox Bio), EA-230 (Exponential Biotherapies), Simdax (Levosimendan; Orion Pharma) and other targeted therapies in the forecast period [2019–2028] will also create a positive impact on the Acute Kidney Injury (AKI) market.

Acute Kidney Injury (AKI) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Acute Kidney Injury (AKI) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Acute Kidney Injury (AKI) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Acute Kidney Injury (AKI)market
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury (AKI)market
  • To understand the future market competition in the Acute Kidney Injury (AKI) market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alloksys
  • AM Pharma
  • Angion Biomedica
  • Astellas Pharma
  • Atox Bio
  • Exponential Biotherapies
  • MORE
1. Key Insights

2. The Report contains

3. Acute Kidney Injury Market (AKI): Overview at a Glance
3.1. Market Share Distribution of AKI in 2017
3.2. Market Share Distribution of AKI in 2028

4. Acute Kidney Injury (AKI): Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Types of Acute Kidney Injury
4.4. Stages Classification
4.5. Risk Factors
4.6. Etiology
4.7. Pathophysiology
4.8. Biomarkers
4.9. Diagnosis

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Incident Patient Population of AKI
5.3. 7MM Total Discharge Diagnosed Population of AKI

6. United States
6.1. Assumptions and Rationale
6.2. Acute Kidney Injury Incident Cases in the US
6.3. Acute Kidney Injury Discharge Diagnosed Cases in the US
6.4. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in the US
6.5. Acute Kidney Injury Risk Factor Associated Cases in the US
6.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the US

7. EU5
7.1. Assumptions and Rationale
7.2. Germany
7.2.1. Acute Kidney Injury Incident Cases in Germany
7.2.2. Acute Kidney Injury Discharge Diagnosed Cases in Germany
7.2.3. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in Germany
7.2.4. Acute Kidney Injury Risk Factor Associated Cases in Germany
7.2.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Germany
7.3. France
7.3.1. Acute Kidney Injury Incident Cases in France
7.3.2. Acute Kidney Injury Discharge Diagnosed Cases in France
7.3.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in France
7.3.4. Acute Kidney Injury Risk Factor Associated Cases in France
7.3.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in France
7.4. Italy
7.4.1. Acute Kidney Injury Incident Cases in Italy
7.4.2. Acute Kidney Injury Discharge Diagnosed Cases in Italy
7.4.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Italy
7.4.4. Acute Kidney Injury Risk Factor Associated Cases in Italy
7.4.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Italy
7.5. Spain
7.5.1. Acute Kidney Injury Incident Cases in Spain
7.5.2. Acute Kidney Injury Discharge Diagnosed Cases in Spain
7.5.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Spain
7.5.4. Acute Kidney Injury Risk Factor Associated Cases in Spain
7.5.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Spain
7.6. United Kingdom
7.6.1. Acute Kidney Injury Incident Cases in the UK
7.6.2. Acute Kidney Injury Discharge Diagnosed Incident Cases in the UK
7.6.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in the UK
7.6.4. Acute Kidney Injury Risk Factor Associated Cases in the UK
7.6.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the UK

8. Japan
8.1.1. Assumptions and Rationale
8.1.2. Acute Kidney Injury Incident Cases in Japan
8.1.3. Acute Kidney Injury Discharge Diagnosed Cases Japan
8.1.4. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Japan
8.1.5. Acute Kidney Injury Risk Factor Associated Cases in Japan
8.1.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Japan

9. Treatment and Prevention

10. Unmet Needs

11. Emerging Therapies
11.1. Key cross competition- Emerging Therapies

12. Emerging Therapies
12.1. EA-230: Exponential Biotherapies
12.1.1. Clinical Development
12.1.2. Clinical Trials Information
12.1.3. Safety and Efficacy
12.1.4. Product Profile
12.2. bRESCAP: Alloksys
12.2.1. Other Developmental Activities
12.2.2. Clinical Trials Information
12.2.3. Safety and Efficacy
12.2.4. Product Profile
12.3. ANG-3777 (BB3) : Angion Biomedica
12.3.1. Other Developmental Activities
12.3.2. Clinical Trials Information
12.3.3. Safety and Efficacy
12.3.4. Product Profile
12.4. QPI-1002: Quark Pharmaceuticals
12.4.1. Other Developmental Activities
12.4.2. Clinical Development
12.4.3. Clinical Trial Information
12.4.4. Safety and Efficacy
12.4.5. Advantages and Disadvantages
12.4.6. Product Profile
12.5. recAP: AM Pharma
12.5.1. Other Developmental Activities
12.5.2. Clinical Development
12.5.3. Clinical Trial Information
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. Reltecimod: AtoxBio
12.6.1. Other Developmental Activities
12.6.2. Clinical Development
12.6.3. Clinical Trial Information
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.7. ASP1128: Astellas Pharma
12.7.1. Other Developmental Activities
12.7.2. Clinical Development
12.7.3. Clinical Trial Information
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.8. Ruconest (Conestat alfa): Pharming Technologies
12.8.1. Other Developmental Activities
12.8.2. Clinical Development
12.8.3. Clinical Trial Information
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. MB-102: MediBeacon
12.9.1. Other Developmental Activities
12.9.2. Clinical Development
12.9.3. Clinical Trial Information
12.9.4. Safety and Efficacy
12.9.5. Product Profile
12.10. Levosimendan (Simdax): Orion Pharma
12.10.1. Clinical Development
12.10.2. Clinical Trial Information
12.10.3. Safety and Efficacy
12.10.4. Product Profile

13. Acute Kidney Injury: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Size of AKI in 7MM

14. United States Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of AKI
14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of AKI
15.1.2. Market Size by Therapies
15.2. France Market Size
15.2.1. Total Market size of AKI
15.2.2. Market Size by Therapies
15.3. Italy Market Size
15.3.1. Total Market size of AKI
15.3.2. Market Size by Therapies
15.4. Spain Market Size
15.4.1. Total Market size of AKI
15.4.2. Market Size by Therapies
15.5. United Kingdom Market Size
15.5.1. Total Market size of AKI
15.5.2. Market Size by Therapies

16. Japan: Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of AKI
16.1.2. Market Size by Therapies

17. Trends in the Cost of Therapies in Acute Kidney Injury

18. Market Drivers

19. Market Barriers

20. Researcher Capabilities

21. Appendix
21.1. Report Methodology

22. Disclaimer

23. About the Publisher

List of Tables:
Table 1 Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification
Table 2 KDIGO Criteria
Table 3 Causes of AKI: Exposures and Susceptibilities for non-specific AKI
Table 4 Biomarkers of AKI
Table 5 RIFLE Criteria for AKI
Table 6 AKIN Criteria for AKI
Table 7 KDIGO Criteria for AKI
Table 8 Total Incident Population of AKI in the 7MM (2017–2028)
Table 9 Total Discharge Diagnosed Population of AKI in the 7MM (2017–2028)
Table 10 AKI Incident Cases in the US (2017–2028)
Table 11 AKI Discharge Diagnosed Cases in the US (2017–2028)
Table 12 AKI Stage-Wise Discharged Diagnosed Cases in the US (2017–2028)
Table 13 AKI Risk Factor Associated Cases in the US (2017–2028)
Table 14 AKI Renal Transplantation Associated Delayed Graft Function Cases in the US (2017–2028)
Table 15 AKI Incident Cases in Germany (2017–2028)
Table 16 AKI Discharge Diagnosed Cases in Germany (2017–2028)
Table 17 AKI Stage-Wise Incident Cases in Germany (2017–2028)
Table 18 AKI Risk Factor Associated Cases in Germany (2017–2028)
Table 19 AKI Renal Transplantation Associated Delayed Graft Function Cases in Germany (2017–2028)
Table 20 AKI Incident Cases in France (2017–2028)
Table 21 AKI Discharge Diagnosed Cases in France (2017–2028)
Table 22 AKI Stage-Wise Discharge Diagnosed Cases in France (2017–2028)
Table 23 AKI Risk Factor Associated Cases in France (2017–2028)
Table 24 AKI Renal Transplantation Associated Delayed Graft Function Cases in France (2017–2028)
Table 25 AKI Incident Cases in Italy (2017–2028)
Table 26 AKI Discharge Diagnosed Cases in Italy (2017–2028)
Table 27 AKI Stage-Wise Discharge Diagnosed Cases in Italy (2017–2028)
Table 28 AKI Risk Factor Associated Cases in Italy (2017–2028)
Table 29 AKI Renal Transplantation Associated Delayed Graft Function Cases in Italy (2017–2028)
Table 30 AKI Incident Cases in Spain (2017–2028)
Table 31 AKI Discharge Diagnosed Cases in Spain (2017–2028)
Table 32 AKI Stage-Wise Discharge Diagnosed Cases in Spain (2017–2028)
Table 33 AKI Risk Factor Associated Cases in Spain (2017–2028)
Table 34 AKI Renal Transplantation Associated Delayed Graft Function Cases in Spain (2017–2028)
Table 35 AKI Incident Cases in the UK (2017–2028)
Table 36 AKI Discharge Diagnosed Cases in the UK (2017–2028)
Table 37 AKI Stage-Wise Discharge Diagnosed Cases in the UK (2017–2028)
Table 38 AKI Risk Factor Associated Cases in the UK (2017–2028)
Table 39 AKI Renal Transplantation Associated Delayed Graft Function Cases in the UK (2017–2028)
Table 40 AKI Incident Cases in Japan (2017–2028)
Table 41 AKI Discharge Diagnosed Cases in Japan (2017–2028)
Table 42 AKI Stage-Wise Discharge Diagnosed Cases in Japan (2017–2028)
Table 43 AKI Risk Factor Associated Cases in Japan (2017–2028)
Table 44 AKI Renal Transplantation Associated Delayed Graft Function Cases in Japan (2017–2028)
Table 45 AKI Renal Replacement Therapy (RRT) Modalities for AKI
Table 46 Key Cross – Emerging Therapies
Table 47 EA-230, Clinical Trials Description, 2019
Table 48 bRESCAP, Clinical Trial Description, 2019
Table 49 ANG-3777 (BB3), Clinical Trial Description, 2019
Table 50 QPI-1002, Clinical Trial Description, 2019
Table 51 recAP, Clinical Trial Description, 2019
Table 52 Reltecimod, Clinical Trial Description, 2019
Table 53 ASP1128, Clinical Trials Description, 2019
Table 54 Ruconest (Conestat alfa), Clinical Trials Description, 2019
Table 55 MB-102, Clinical Trials Description, 2019
Table 56 Levosimendan (Simdax), Clinical Trials Description, 2019
Table 57 7 Major Market Size of AKI in USD Million (2017–2028)
Table 58 Market Size of AKI in the US, USD Million (2017–2028)
Table 59 Market size of AKI by therapies in the US, in USD Million (2017–2028)
Table 60 Market Size of AKI in Germany, USD Million (2017–2028)
Table 61 Market size of AKI by therapies in Germany, in USD Million (2017–2028)
Table 62 Market Size of AKI in France, USD Million (2017–2028)
Table 63 Market size of AKI by therapies in France, in USD Million (2017–2028)
Table 64 Market Size of AKI in Italy, USD Million (2017–2028)
Table 65 Market size of AKI by therapies in Italy, in USD Million (2017–2028)
Table 66 Market Size of AKI in Spain, USD Million (2017–2028)
Table 67 Market size of AKI by therapies in Spain, in USD Million (2017–2028)
Table 68 Market Size of AKI in the UK, USD Million (2017–2028)
Table 69 Market size of AKI by therapies in the UK, in USD Million (2017–2028)
Table 70 Market Size of AKI in Japan, USD Million (2017–2028)
Table 71 Market size of AKI by therapies in Japan, in USD Million (2017–2028)
Table 72 Trends in the Cost of Therapies in Acute Kidney Injury

List of Figures:
Figure 1 Types of Acute Kidney Injury
Figure 2 Risk factors associated with Acute Kidney Injury
Figure 3 Common Causes of AKI
Figure 4 Pathophysiology of AKI
Figure 5 Biomarkers of AKI
Figure 6 Total Incident Patient Population of AKI in the 7MM (2017–2028)
Figure 7 Total Discharge Diagnosed Population of AKI in the 7MM (2017–2028)
Figure 8 AKI Incident Cases in the US (2017–2028)
Figure 9 AKI Discharge Diagnosed Cases in the US (2017–2028)
Figure 10 AKI Stage-Wise Discharged Diagnosed Cases in the US (2017–2028)
Figure 11 AKI Risk Factor Associated Cases in the US (2017–2028)
Figure 12 AKI Renal Transplantation Associated Delayed Graft Function Cases in the US (2017–2028)
Figure 13 AKI Incident Cases in Germany (2017–2028)
Figure 14 AKI Discharge Diagnosed Cases in Germany (2017–2028)
Figure 15 AKI Stage-Wise Incident Cases in Germany (2017–2028)
Figure 16 AKI Risk Factor Associated Cases in Germany (2017–2028)
Figure 17 AKI Renal Transplantation Associated Delayed Graft Function Cases in Germany (2017–2028)
Figure 18 AKI Incident Cases in France (2017–2028)
Figure 19 AKI Discharge Diagnosed Cases in France (2017–2028)
Figure 20 AKI Stage-Wise Discharge Diagnosed Cases in France (2017–2028)
Figure 21 AKI Risk Factor Associated Cases in France (2017–2028)
Figure 22 AKI Renal Transplantation Associated Delayed Graft Function Cases in France (2017–2028)
Figure 23 AKI Incident Cases in Italy (2017–2028)
Figure 24 AKI Discharge Diagnosed Cases in Italy (2017–2028)
Figure 25 AKI Stage-Wise Discharge Diagnosed Cases in Italy (2017–2028)
Figure 26 AKI Risk Factor Associated Cases in Italy (2017–2028)
Figure 27 AKI Renal Transplantation Associated Delayed Graft Function Cases in Italy (2017–2028)
Figure 28 AKI Incident Cases in Spain (2017–2028)
Figure 29 AKI Discharge Diagnosed Cases in Spain 2017–2028)
Figure 30 AKI Stage-Wise Discharge Diagnosed Cases in Spain (2017–2028)
Figure 31 AKI Risk Factor Associated Cases in Spain (2017–2028)
Figure 32 AKI Renal Transplantation Associated Delayed Graft Function Cases in Spain (2017–2028)
Figure 33 AKI Incident Cases in the UK (2017–2028)
Figure 34 AKI Discharge Diagnosed Cases in the UK (2017–2028)
Figure 35 AKI Stage-Wise Discharge Diagnosed Cases the UK (2017–2028)
Figure 36 AKI Risk Factor Associated Cases in the UK (2017–2028)
Figure 37 AKI Renal Transplantation Associated Delayed Graft Function Cases in the UK (2017–2028)
Figure 38 AKI Incident Cases of in Japan (2017–2028)
Figure 39 AKI Discharge Diagnosed Incident Cases in Japan (2017–2028)
Figure 40 AKI Stage-Wise Discharge Diagnosed Cases in Japan (2017–2028)
Figure 41 AKI Risk Factor Associated Cases in Japan (2017–2028)
Figure 42 AKI Renal Transplantation Associated Delayed Graft Function Cases in Japan (2017–2028)
Figure 43 Global Mortality of AKI
Figure 44 Stage-based management of Acute Kidney Injury (AKI)
Figure 45 Unmet Needs for AKI
Figure 46 7 Major Market Size of AKI in USD Million (2017–2028)
Figure 47 Market Size of AKI in the US, USD Million (2017–2028)
Figure 48 Market size of AKI by therapies in the US, in USD Million (2017–2028)
Figure 49 Market Size of AKI in Germany, USD Million (2017–2028)
Figure 50 Market size of AKI by therapies in Germany, in USD Million (2017–2028)
Figure 51 Market Size of AKI in France, USD Million (2017–2028)
Figure 52 Market size of AKI by therapies in France, in USD Million (2017–2028)
Figure 53 Market Size of AKI in Italy, USD Million (2017–2028)
Figure 54 Market size of AKI by therapies in Italy, in USD Million (2017–2028)
Figure 55 Market Size of AKI in Spain, USD Million (2017–2028)
Figure 56 Market size of AKI by therapies in Spain, in USD Million (2017–2028)
Figure 57 Market Size of AKI in the UK, USD Million (2017–2028)
Figure 58 Market size of AKI by therapies in the UK, in USD Million (2017–2028)
Figure 59 Market Size of AKI in Japan, USD Million (2017–2028)
Figure 60 Market size of AKI by therapies in Japan, in USD Million (2017–2028)
Figure 61 Market Drivers
Figure 62 Market Barriers

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Exponential Biotherapies
  • Alloksys
  • Angion Biomedica
  • Quark Pharmaceuticals
  • AM Pharma
  • Atox Bio
  • Astellas Pharma
  • Pharming Technologies
  • MediBeacon
  • Orion Pharma
Note: Product cover images may vary from those shown
Adroll
adroll